BORA PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 785 TWD | +4.81% |
|
+5.37% | +22.85% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,609 | 10,634 | 12,446 | 31,121 | 64,612 | 79,121 | - |
| Enterprise Value (EV) 1 | 6,574 | 12,501 | 13,431 | 31,121 | 66,207 | 83,699 | 79,747 |
| P/E ratio | 18 x | 18.4 x | 16.7 x | 22.7 x | 21.2 x | 22.7 x | 16.7 x |
| Yield | 1.4% | 1.02% | 1.9% | - | 1.88% | 1.88% | 1.89% |
| Capitalization / Revenue | 3.67 x | 5.91 x | 2.54 x | 2.97 x | 4.55 x | 4.46 x | 3.69 x |
| EV / Revenue | 4.3 x | 6.95 x | 2.74 x | 2.97 x | 4.66 x | 4.71 x | 3.72 x |
| EV / EBITDA | 14.2 x | 34.1 x | 10.7 x | 13.8 x | 11.3 x | 13.8 x | 11.2 x |
| EV / FCF | -14.1 x | 438 x | 12.5 x | 17.1 x | 15.2 x | 20 x | 16.4 x |
| FCF Yield | -7.08% | 0.23% | 7.99% | 5.86% | 6.58% | 5% | 6.08% |
| Price to Book | 3.33 x | 4.29 x | 3.99 x | 6.87 x | 7.11 x | 8.04 x | 5.56 x |
| Nbr of stocks (in thousands) | 91,161 | 96,417 | 96,687 | 97,524 | 101,115 | 100,791 | - |
| Reference price 2 | 61.52 | 110.3 | 128.7 | 319.1 | 639.0 | 785.0 | 785.0 |
| Announcement Date | 3/16/20 | 3/29/21 | 3/9/22 | 3/20/23 | 3/7/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,529 | 1,800 | 4,900 | 10,494 | 14,200 | 17,756 | 21,448 |
| EBITDA 1 | 464.5 | 367.1 | 1,256 | 2,263 | 5,855 | 6,049 | 7,100 |
| EBIT 1 | 344.8 | 226.1 | 1,046 | 1,922 | 5,249 | 5,286 | 6,807 |
| Operating Margin | 22.55% | 12.56% | 21.35% | 18.32% | 36.97% | 29.77% | 31.74% |
| Earnings before Tax (EBT) 1 | 325.4 | 595.4 | 1,024 | 1,840 | 4,064 | 4,994 | 6,288 |
| Net income 1 | 305 | 578.4 | 749.7 | 1,392 | 3,030 | 3,498 | 4,750 |
| Net margin | 19.95% | 32.14% | 15.3% | 13.26% | 21.34% | 19.7% | 22.15% |
| EPS 2 | 3.411 | 5.989 | 7.703 | 14.09 | 30.20 | 34.52 | 46.97 |
| Free Cash Flow 1 | -465.6 | 28.56 | 1,073 | 1,822 | 4,357 | 4,189 | 4,852 |
| FCF margin | -30.44% | 1.59% | 21.9% | 17.36% | 30.69% | 23.59% | 22.62% |
| FCF Conversion (EBITDA) | - | 7.78% | 85.43% | 80.54% | 74.42% | 69.25% | 68.33% |
| FCF Conversion (Net income) | - | 4.94% | 143.14% | 130.92% | 143.8% | 119.76% | 102.15% |
| Dividend per Share 2 | 0.8635 | 1.123 | 2.449 | - | 12.00 | 14.72 | 14.83 |
| Announcement Date | 3/16/20 | 3/29/21 | 3/9/22 | 3/20/23 | 3/7/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,150 | 1,117 | 1,355 | 2,724 | 5,298 | 4,781 | 3,139 | 3,075 | 3,206 | 2,857 | 4,852 | 4,918 | 5,130 | 5,219 | 5,374 |
| EBITDA 1 | 237.7 | 305 | 421.5 | - | - | 1,681 | 1,485 | 1,370 | 1,320 | 1,083 | 1,609 | 1,788 | 2,037 | - | - |
| EBIT 1 | 186.3 | 251.6 | 369.4 | 643.3 | 657.8 | 1,547 | 1,347 | 1,219 | 1,320 | 892 | 1,308 | 1,442 | 1,534 | 1,527 | 1,569 |
| Operating Margin | 16.2% | 22.52% | 27.27% | 23.62% | 12.42% | 32.37% | 42.91% | 39.64% | 41.18% | 31.22% | 26.97% | 29.31% | 29.91% | 29.26% | 29.2% |
| Earnings before Tax (EBT) 1 | 182.3 | 253 | 369.1 | 782 | 435.9 | 1,442 | 1,019 | 923 | 679.7 | 983.5 | 1,211 | 1,280 | 1,404 | 1,378 | 1,427 |
| Net income 1 | 140.1 | 179.2 | 240 | 568.9 | 403.9 | 1,039 | 692 | 733.2 | 565.6 | 716.1 | 911.2 | 958.2 | 1,063 | 1,016 | 1,046 |
| Net margin | 12.18% | 16.04% | 17.72% | 20.88% | 7.62% | 21.74% | 22.05% | 23.84% | 17.64% | 25.06% | 18.78% | 19.48% | 20.72% | 19.46% | 19.47% |
| EPS 2 | 1.420 | 1.826 | 2.463 | 5.813 | 4.003 | 10.49 | 8.810 | 7.280 | 6.090 | 6.880 | 9.006 | 9.474 | 10.51 | 10.03 | 10.34 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/22 | 5/10/22 | 8/12/22 | 11/14/22 | 3/20/23 | 5/12/23 | 8/14/23 | 11/9/23 | 3/7/24 | 5/14/24 | - | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 965 | 1,867 | 985 | - | 1,595 | 4,578 | 626 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.078 x | 5.087 x | 0.7841 x | - | 0.2724 x | 0.7568 x | 0.0882 x |
| Free Cash Flow 1 | -466 | 28.6 | 1,073 | 1,822 | 4,357 | 4,189 | 4,852 |
| ROE (net income / shareholders' equity) | 20.5% | 28.1% | 26.7% | 36.2% | 44.5% | 32.4% | 41.2% |
| ROA (Net income/ Total Assets) | 10.9% | 11.1% | 10.4% | 9.24% | 12.7% | 13.1% | 13% |
| Assets 1 | 2,807 | 5,192 | 7,188 | 15,067 | 23,907 | 26,700 | 36,678 |
| Book Value Per Share 2 | 18.50 | 25.70 | 32.20 | 46.40 | 89.80 | 97.60 | 141.0 |
| Cash Flow per Share 2 | 2.580 | 1.840 | 12.70 | - | 44.60 | 35.30 | 33.80 |
| Capex 1 | 697 | 149 | 163 | 188 | 256 | 283 | 234 |
| Capex / Sales | 45.6% | 8.29% | 3.34% | 1.79% | 1.8% | 1.59% | 1.09% |
| Announcement Date | 3/16/20 | 3/29/21 | 3/9/22 | 3/20/23 | 3/7/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
785
TWD
Average target price
894.4
TWD
Spread / Average Target
+13.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.85% | 2.33B | |
| +42.69% | 750B | |
| +34.11% | 606B | |
| -6.87% | 356B | |
| +18.74% | 326B | |
| +6.76% | 286B | |
| +18.08% | 246B | |
| -3.44% | 213B | |
| +11.35% | 213B | |
| +2.64% | 167B |
- Stock Market
- Equities
- 6472 Stock
- Financials Bora Pharmaceuticals Co., LTD.
